The Global Health Body Issues Warning Over Acute Scarcity of Weight-Loss Injections
Less than one in 10 individuals that would benefit from obesity jabs including Wegovy can access them, caution the World Health Organization as it issues its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a chronic disease that can be treated with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major hurdles to universal availability to the jabs that can help people shift substantial weight, notes the body.
Skinny Jab Supply Crisis
Even in the current most favorable case, the manufacturing of such drugs would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The guideline urges countries and companies to widen availability, by measures including patent sharing.
Exclusive production rights on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to slow digestion, curb appetite and boost feelings of fullness so people consume fewer calories.
Individuals commonly start to lose weight within a few weeks of commencing the weekly injections.
Research points to users may see weight return a year later of discontinuing the medication, as their normal food cravings come back.
To be carrying excess weight increases your risk for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
